

Fourth Quarter 2009 Earnings Call

Supplemental Slides



HEALTHSOUTH

Forward-Looking Statements

The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect our current views with respect to future events and financial performance. These estimates, projections and other forward-looking information are based on assumptions that HealthSouth believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.

There can be no assurance that any estimates, projections or forward-looking information will be realized.

All such estimates, projections and forward-looking information speak only as of the date hereof. HealthSouth undertakes no duty to publicly update or revise the information contained herein.

You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in our Form 10-Q for quarters ended March 31, 2009, June 30, 2009, and September 30, 2009, and the Form 10-K for the year ended December 31, 2009, when filed, and in other documents we previously filed with the SEC, many of which are beyond our control, that may cause actual results to differ materially from the views, beliefs and estimates expressed herein.

Note Regarding Presentation of Non-GAAP Financial Measures

The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. Our Form 8-K, dated February 22, 2010, to which the following supplemental slides are attached as Exhibit 99.2, provides further explanation and disclosure regarding our use of non-GAAP financial measures and should be read in conjunction with these supplemental slides.

Table of Contents

Highlights.....	4 - 5
Revenues.....	6
Expenses.....	7
Adjusted Consolidated EBITDA.....	8
Adjusted Income per Diluted Share.....	9 - 10
Free Cash Flow Reconciliation.....	11 - 12
Debt Reduction & Liquidity.....	13
2010 Guidance.....	14
Business Outlook.....	15
Appendix.....	16
Operational Excellence.....	17 - 19
Readmission Rates.....	20
Organic Growth.....	21
Regulatory Uncertainty.....	22
Revenues (YE).....	23
Expenses (YE).....	24
Revenues (Sequential).....	25
Expenses (Sequential).....	26
Operational and Labor Metrics.....	27
Payment Sources.....	28
Debt Maturities.....	29
Interest Rate Swaps.....	30
Debt Schedule.....	31
Non-Operating Cash/Tax Position.....	32
Outstanding Share Summary.....	33
US GAAP Reconciliations.....	34 - 35

Highlights (Q4 2009)

Goal One – Organic Growth

- ✓ Achieved 4.6% quarter-over-quarter discharge growth.
 - Same store discharge growth was 4.2%.
- ✓ Revenue growth of 5.5%.
 - Driven by higher discharge volume and Medicare market basket increase of 2.5% effective October 1, 2009.
- ✓ High-quality, cost-effective, patient care.
 - Continued labor productivity gains.

Goal Two – Delever the Balance Sheet

- ✓ Reduced debt by \$34.2 million during the quarter.
- ✓ Completed amendment and extension of the term loan facility and refinancing of floating rate notes due 2014.

Goal Three – Disciplined, Opportunistic Growth

- ✓ Successful start-up of Mesa, AZ, 40-bed inpatient rehabilitation hospital.
- ✓ Expanded joint venture with St. Vincent Health System in Little Rock, AR, through the purchase of a 23-bed rehabilitation unit.
- ✓ Acquired a rehabilitation unit in Altoona, PA, through a newly formed joint venture and relocated its operations to one of our hospitals.

Highlights (2009)

Goal One – Organic Growth

- ✓ Achieved 5.4% year-over-year discharge growth through our sales and marketing initiative.
- ✓ Successful start-up of Mesa, AZ, 40-bed inpatient rehabilitation hospital.
- ✓ Added capacity for approximately 100 beds at existing hospitals.
- ✓ Broke ground on a 40-bed inpatient rehabilitation hospital in Loudoun County, VA.

Goal Two – Delever the Balance Sheet

- ✓ Reduced debt by \$151 million and leverage from 5.3x to 4.3x⁽¹⁾.
- ✓ Completed capital structure enhancements.

Goal Three – Disciplined, Opportunistic Growth

- ✓ Expanded joint venture with St. Vincent Health System in Little Rock, AR, through the purchase of a 23-bed rehabilitation unit.
- ✓ Acquired a rehabilitation unit in Altoona, PA, through a newly formed joint venture and relocated its operations to one of our hospitals.
- ✓ Announced that our joint venture with Wellmont Health Systems will open a new, 25-bed inpatient rehabilitation hospital in Bristol, VA, in Q3 2010.

⁽¹⁾ Based on four quarter trailing Adjusted Consolidated EBITDA of \$383.0 million and \$341.2 million, respectively; see related debt schedule on slide 31 and reconciliation to GAAP on slides 34 through 35.

Revenues (Q4 2009 vs. Q4 2008)

(Millions)	4th Qtr. 2009	4th Qtr. 2008	Favorable (Unfavorable) Change
Inpatient	\$ 445.7	\$ 416.5	7.0%
Outpatient and other	40.5	44.3	(8.6%)
Consolidated net operating	<u>\$ 486.2</u>	<u>\$ 460.8</u>	<u>5.5%</u>

(Actual Amounts)

Discharges	28,772	27,516	4.6%
Net patient revenue / discharge	\$ 15,491	\$ 15,137	2.3%

- **Inpatient revenue growth was driven by strong discharge volumes in Q4 2009 despite tough comparisons in Q4 2008.**
 - Volume growth was driven by the sustained sales and marketing effort.
 - Same store discharge growth was 4.2%.
 - Pricing reflects 2.5% Medicare market basket increase effective October 1, 2009.
- **Outpatient revenue declined as a result of 10 fewer outpatient satellites quarter over quarter.**

Expenses (Q4 2009 vs. Q4 2008)

(Millions)	<u>4th Qtr. 2009</u>	<u>4th Qtr. 2008</u>	<u>Favorable/ (Unfavorable) Change</u>
Salaries and benefits	\$ 243.7	\$ 232.1	(5.0%)
Percent of net operating revenues	50.1%	50.4%	30 bps
EPOB (employees per occupied bed)	3.55	3.64	2.5%
Hospital-related expenses	\$ 119.2	\$ 112.1	(6.3%)
(other operating, supplies, occupancy, bad debts)			
Percent of net operating revenues	24.5%	24.3%	(20) bps
General and administrative	\$ 24.7	\$ 23.5	(5.1%)
(excludes share-based compensation)			
Percent of net operating revenues	5.1%	5.1%	0 bps

- **Salaries and benefits increased as a result of an October 1, 2009, 2.3% merit increase.**
 - Continued improvement on labor productivity demonstrated by lower EPOB.
- **Hospital-related expenses increased as a result of higher discharge volume.**

Adjusted Consolidated EBITDA ⁽¹⁾

(Millions)

<u>4th Qtr. 2009</u>	<u>4th Qtr. 2008</u>	<u>Change</u>	
		<u>\$</u>	<u>%</u>
\$ 94.7	\$ 87.5	\$ 7.2	8.2%

<u>Year-End 2009</u>	<u>Year-End 2008</u>	<u>Change</u>	
		<u>\$</u>	<u>%</u>
\$ 383.0	\$ 341.2	\$ 41.8	12.3%

- **Improvements driven by:**

- Increased volumes
- Improved labor productivity
- Disciplined expense management
- 2.5% Medicare market basket increase effective October 1, 2009

(1) Reconciliation to GAAP provided on slides 34 through 35.

Adjusted Income per Diluted Share (4Q 2009)


(Millions, except per share data)	4th Qtr.	4th Qtr.	Change	
	2009	2008	\$	%
Adjusted income from continuing operations ⁽¹⁾	\$ 24.1	\$ 24.3	\$ (0.2)	(0.8%)
	Per Share		Per Share	
Adjusted income from continuing operations per diluted share ⁽¹⁾	\$ 0.22	\$ 0.24	\$ (0.02)	(8.3%)

- **The improvement in adjusted earnings per share, driven by higher Adjusted Consolidated EBITDA and lower interest expense, was offset by a \$15.6 million loss on early extinguishment of debt.**
 - Interest expense was lower as a result of lower debt balances and a lower LIBOR rate.

⁽¹⁾ Reconciliation to GAAP provided on slides 34 through 35.

Adjusted Income per Diluted Share (Year-End)

(Millions, except per share data)	Year-End	Year-End	Change	
	2009	2008	\$	%
Adjusted income from continuing operations ⁽¹⁾	\$ 149.6	\$ 72.9	\$ 76.7	105.2%
Adjusted income from continuing operations per diluted share ⁽¹⁾	Per Share \$ 1.45	Per Share \$ 0.76	Per Share \$ 0.69	Per Share 90.8%



⁽¹⁾ Reconciliation to GAAP provided on slides 34 through 35.

Free Cash Flow Reconciliation: Adjusted Consolidated EBITDA ⁽¹⁾ to Net Cash Provided by Operating Activities

	4th Qtr.		Year-End	
	2009	2008	2009	2008
Adjusted Consolidated EBITDA	\$ 94.7	\$ 87.5	\$ 383.0	\$ 341.2
Provision for doubtful accounts	7.8	6.9	33.1	27.0
Professional fees—accounting, tax, and legal	(3.8)	(31.5)	(8.8)	(44.4)
Interest expense and amortization of debt discounts and fees	(30.8)	(28.4)	(125.8)	(159.5)
(Gain) loss on sale of investments	(0.2)	1.5	(0.8)	1.4
UBS Settlement proceeds, gross	-	-	100.0	-
Equity in net income of nonconsolidated affiliates	(1.8)	(2.8)	(4.6)	(10.6)
Net income attributable to noncontrolling interests in continuing operations	8.2	8.1	33.4	29.8
Amortization of debt discounts and fees	1.7	1.6	6.6	6.5
Distributions from nonconsolidated affiliates	2.1	3.3	8.6	10.9
Current portion of income tax benefit	4.1	50.1	7.3	73.8
Change in assets and liabilities	(33.3)	(30.2)	(0.8)	(53.1)
Change in government, class action, and related settlements liability	(0.2)	(0.1)	(11.2)	(7.4)
Other operating cash (used in) provided by discontinued operations	(4.1)	11.9	(13.5)	11.4
Other	(0.4)	-	(0.4)	0.2
Net cash provided by operating activities	\$ 44.0	\$ 77.9	\$ 406.1	\$ 227.2

⁽¹⁾ Notes on page 35.

Free Cash Flow Reconciliation: Net Cash provided by Operating Activities to Adjusted Free Cash Flow


(Millions)	4th Qtr.		Year-End	
	2009	2008	2009	2008
Net cash provided by operating activities	\$ 44.0	\$ 77.9	\$ 406.1	\$ 227.2
Impact of discontinued operations	4.1	(11.9)	13.5	(11.4)
Net cash provided by operating activities of continuing operations	48.1	66.0	419.6	215.8
Capital expenditures for maintenance ⁽¹⁾	(9.6)	(17.4)	(34.1)	(42.6)
Net settlements on interest rate swaps	(11.9)	(6.8)	(42.2)	(20.7)
Dividends paid on convertible perpetual preferred stock	(6.5)	(6.5)	(26.0)	(26.0)
Distributions paid to noncontrolling interests of consolidated affiliates	(9.9)	(7.1)	(32.7)	(33.4)
Non-recurring items:				
UBS Settlement proceeds, less fees to derivative plaintiffs' attorneys	-	-	(73.8)	-
Cash paid for professional fees - accounting, tax, and legal	3.8	5.3	15.3	18.2
Cash paid for government, class action, and related settlements	0.2	-	11.2	7.4
State and federal income tax refunds related prior periods	(4.2)	(63.1)	(63.7)	(90.4)
Adjusted free cash flow	\$ 10.0 ⁽²⁾	\$ (29.6)	\$ 173.6	\$ 28.3

⁽¹⁾ Includes capital expenditures for the hospital refresh program.

⁽²⁾ Reflects seasonal use of cash related to interest and insurance payments.

Debt Reduction and Liquidity

(\$ Billions)



Debt to EBITDA 6.3x 6.3x 5.3x 4.3x ⁽¹⁾

Year-End 2011 Goal: 3.5x to 4.0x

Liquidity

	Dec. 31, 2009	Dec. 31, 2008
Cash Available	\$ 80.9	\$ 32.1
Revolver Total Line	\$ 400.0	\$ 400.0
Less:		
– Draws	-	(40.0)
– Letters of credit	-	(52.7)
Available	\$ 400.0	\$ 307.3
Total Liquidity	\$ 480.9	\$ 339.4

⁽¹⁾ Based on four quarter trailing Adjusted Consolidated EBITDA of \$383.0 million; see related debt schedule on slide 31, and reconciliation to GAAP on slides 34 through 35.

2010 Guidance ⁽¹⁾

	Actual 2009	Guidance 2010
Adjusted Consolidated EBITDA⁽¹⁾	\$383.0 million	\$397 to \$407 million
Adjusted earnings per share ⁽¹⁾⁽²⁾	\$1.45 per share	\$1.60 to \$1.70 per share

(1) Reconciliation to GAAP provided on slides 34 through 35.

(2) Adjusted income from continuing operations per diluted share.

Business Outlook


Deleveraging, Growth, Reform and Sector Regulation

	2010	2011	2012	2013
Deleveraging	3.5x to 4.0x Debt to EBITDA (by YE 2011) (Exclusive of any E&Y settlement)			
Growth	Organic growth through capacity expansion and de novos (~ \$60 million in 2010)			
	IRF acquisitions/joint ventures			
			Acquisitions of other, complementary post-acute services	
Reform	No change		Unknown at this time	
1.Pricing				
2.Bundling	Pilot/Demonstration Projects			
Sector Regulation	<ul style="list-style-type: none"> • LTCH: admission criteria; 25% Rule; MMSEA extension • Home Health: outliers; reimbursement methodology 			




Appendix

Operational Excellence: Sustained Market Share Gains



- ✓ HealthSouth's volume growth has outpaced competitors'
- ✓ TeamWorks = standardized sales & marketing
- ✓ Capacity expansions will help facilitate organic growth:
 - ~ 100 new beds 2009
 - ~ 100 new beds 2010



(1) Data provided by UDS_{MR}, a data gathering and analysis organization for the rehabilitation industry; represents ~ 65-70% of industry, including 90 HealthSouth sites.


(2) Includes 90 consolidated HealthSouth inpatient rehab hospitals and six long-term acute-care hospitals.

Operational Excellence = “High-Quality” Care

FIM Gain = Change in Functional Independent Measurement (based on an 18 point assessment) from Admission to Discharge


LOS Efficiency = Functional gain divided by length of stay

FIM Gain



* Average = Expected, Risk-adjusted FIM Change Average

LOS Efficiency



** Average = Expected, Risk-adjusted LOS Efficiency

Source: UDSmr Database – On Demand Reports 2008 Year End Report

Operational Excellence = “Cost-Effective” Care

CMS Fiscal Year 2010 IRF Rate Setting File Analysis ⁽¹⁾

	Freestanding ⁽²⁾	Units ⁽²⁾	Total	HealthSouth Hospitals ⁽²⁾
Number of IRFs	228	953	1,181	94
Average # of Discharges per IRF	649	237	316	822
Outlier Payments as % of Total Payments	1.32%	4.08%	3.00%	0.43%
Average Estimated Total Payment per Discharge for FY 2010	\$16,452	\$16,741	\$16,626	\$15,996
Average Estimated Cost per Discharge for FY 2010	\$14,021	\$17,207	\$15,945	\$12,633

Notes:

- (1) All data provided was filtered and compiled from the Centers for Medicare and Medicaid Services (CMS) Fiscal Year 2010 IRF rate setting final rule file found at http://www.cms.hhs.gov/InpatientRehabFacPPS/07_DataFiles.asp#TopOfPage. The data presented was developed entirely by CMS and is based on its definitions which are different in form and substance from the criteria HealthSouth uses for external reporting purposes. Because CMS does not provide its detailed methodology, HealthSouth is not able to reconstruct the CMS projections or the calculation.
- (2) The CMS file contains data for each of the 1,181 inpatient rehabilitation facilities used to estimate the policy updates for the FY 2010 Final IRF-PPS Rule. Most of the data represents historical information from the CMS fiscal year 2008 period and does not reflect the same HealthSouth hospitals in operation today. The data presented was separated into three categories: Freestanding, Units, and HealthSouth. HealthSouth is a subset of Freestanding and the Total.

IRFs have Lower Readmission Rates

Post-Acute Care ("PAC") Setting	Percent Discharged from Hospital to PAC Setting	Percent Rehospitalized after Using PAC Setting	Percent Died in PAC Setting
Skilled Nursing Facility	17.3%	22.0%	5.4%
Home Health	16.0%	18.1%	0.8%
Long-Term Care Hospital	1.0%	10.0%	15.5%
Inpatient Rehabilitation	3.2%	9.4%	0.4%
Inpatient Psychiatric	0.5%	8.7%	0.4%
Hospice	2.1%	4.5%	82.2%
TOTAL	40.0%	18.0%	6.2%

Note: Use of home health care and hospice is based on care that starts within three days of discharge. Other PAC care starts within one day of discharge. Home health use includes episodes that overlap an inpatient stay.

Source: Medicare Payment Advisory Commission, "A Data Book: Healthcare spending and the Medicare program," Chart 9-3 (June 2008)

Organic Growth

Capacity expansions:

- Approximately 100 beds added in 2010.
- Average investment per bed including renovation:

– \$100K to \$250K



Cash pay-back:
2 – 4 years

De novos:

<u>Location</u>	<u>Installed Beds</u>	<u>Operational Date</u>
Mesa, AZ	40 Beds	Q309
Loudoun County, VA	40 Beds	Q210
Bristol, VA	25 Beds	Q310



Cash pay-back:
6 - 7 years

Acquisitions:

- Expanded joint venture with St. Vincent Health System in Little Rock, AR, through the purchase of a 23-bed rehabilitation unit.
- Acquired the rehabilitation unit in Altoona, PA, through a newly formed joint venture and relocated its operations to one of our hospitals.

Regulatory Uncertainty

Future Regulatory Risk	IRF	SNF	LTCH	HH
1. Re-basing payment system	No	Yes; RUGS IV begins 10/01/10 (Senate bill delays until 10/01/11)	No	Yes; would be required as part of healthcare reform (2014 Senate bill; 2011 House bill)
2. Major outlier payment adjustments	No	No	Yes; will occur when MMSEA moratorium expires (short stay outliers)	Yes; 10% cap per agency
3. Upcoding adjustments	No	Yes; occurring in FY 2010	Yes; occurring in RY 2010 and, possibly, RY 2011	Yes; occurring in CYs 2010 and 2011
4. Patient criteria	No; 60% Rule already in place	No	Study dictated as part of MMSEA	No
5. Healthcare reform: <ul style="list-style-type: none"> – Market Basket update reductions – Productivity Adjustments – Bundling – "Super" MedPAC 	Unknown at this time	Unknown at this time	Unknown at this time	Unknown at this time
6. Other	N/A	N/A	25% Rule will be reinstated when MMSEA moratorium expires	N/A

Sources: Senate Reform Bill, CMS Regulatory published rules and MMSEA

Revenues (Year-End)

	<u>2009</u>	<u>2008</u>	Favorable (Unfavorable) Change
(Millions)			
Inpatient	\$ 1,743.4	\$ 1,651.7	5.6%
Outpatient and other	167.7	177.8	(5.7%)
Consolidated net operating	<u>\$ 1,911.1</u>	<u>\$ 1,829.5</u>	<u>4.5%</u>
(Actual Amounts)			
Discharges	112,975	107,184	5.4%
Net patient revenue / discharge	\$ 15,432	\$ 15,410	0.1%

Expenses (Year-End)

(Millions, except percent)	<u>2009</u>	<u>2008</u>	<u>Favorable/ (Unfavorable) Change</u>
Salaries and benefits	\$ 948.8	\$ 928.2	(2.2%)
Percent of net operating revenues	49.6%	50.7%	110 bps
EPOB (employees per occupied bed)	3.53	3.62	2.5%
Hospital related expenses	\$ 464.5	\$ 448.9	(3.5%)
(other operating, supplies, occupancy, bad debts)			
Percent of net operating revenues	24.3%	24.5%	20 bps
General and administrative	\$ 91.1	\$ 93.8	2.9%
(excludes share-based compensation)			
Percent of net operating revenues	4.8%	5.1%	30 bps

Revenues (Sequential)

	4th Qtr. 2009	3rd Qtr. 2009	Favorable (Unfavorable) Change
(Millions, except percent)			
Inpatient	\$ 445.7	\$ 429.2	3.8%
Outpatient and other	40.5	41.2	(1.7%)
Consolidated net operating	<u>\$ 486.2</u>	<u>\$ 470.4</u>	<u>3.4%</u>
(Actual Amounts)			
Discharges	28,772	28,125	2.3%
Net patient revenue / discharge	\$ 15,491	\$ 15,260	1.5%

Expenses (Sequential)

(Millions, except percent)	<u>4th Qtr. 2009</u>	<u>3rd Qtr. 2009</u>	<u>Favorable (Unfavorable) Change</u>
Salaries and benefits	\$ 243.7	\$ 234.0	(4.1%)
Percent of net operating revenues	50.1%	49.7%	(40) bps
EPOB (employees per occupied bed)	3.55	3.58	0.8%
Hospital related expenses	\$ 119.2	\$ 113.9	(4.7%)
(other operating, supplies, occupancy, bad debts)			
Percent of net operating revenues	24.5%	24.2%	(30) bps
General and administrative	\$ 24.7	\$ 22.6	(9.3%)
(excludes share-based compensation)			
Percent of net operating revenues	5.1%	4.8%	(30) bps

Operational and Labor Metrics ⁽¹⁾

	Q4 2009	Q3 2009	Q2 2009	Q1 2009	Q4 2008	Q3 2008	Q2 2008	Q1 2008	2009	2008
	(In Millions)									
Net patient revenue-inpatient	\$ 445.7	\$ 429.2	\$ 437.2	\$ 431.3	\$ 416.5	\$ 409.3	\$ 408.5	\$ 417.4	\$ 1,743.4	\$ 1,651.7
Net patient revenue-outpatient and other revenues	40.5	41.2	44.4	41.6	44.3	43.5	45.6	44.4	167.7	177.8
Net operating revenues	\$ 486.2	\$ 470.4	\$ 481.6	\$ 472.9	\$ 460.8	\$ 452.8	\$ 454.1	\$ 461.8	\$ 1,911.1	\$ 1,829.5
	(Actual Amounts)									
Discharges ⁽²⁾	28,772	28,125	28,379	27,699	27,516	26,666	26,831	26,171	112,975	107,184
Outpatient visits	265,067	281,913	291,944	283,621	290,018	308,055	317,151	303,702	1,122,545	1,218,926
Average length of stay	14.0	14.3	14.4	14.6	14.3	14.7	14.7	15.2	14.3	14.7
Occupancy %	66.5%	67.0%	69.4%	69.9%	66.1%	66.0%	67.3%	67.5%	67.3%	66.8%
# of licensed beds	6,572	6,507	6,454	6,443	6,463	6,476	6,441	6,485	6,572	6,463
Occupied beds	4,370	4,360	4,479	4,504	4,272	4,274	4,335	4,377	4,423	4,317
Full-time equivalents (FTEs) ⁽³⁾	15,428	15,528	15,590	15,469	15,445	15,633	15,597	15,215	15,504	15,473
Contract labor	64	60	120	143	116	135	218	202	97	168
Total FTE and contract labor	15,492	15,588	15,710	15,612	15,561	15,768	15,815	15,417	15,601	15,641
EPOB ⁽⁴⁾	3.55	3.58	3.51	3.47	3.64	3.69	3.65	3.52	3.53	3.62

(1) Numbers have been reclassified to reflect current continuing operations.

(2) Represents discharges from HealthSouth's 90 consolidated hospitals, which includes Mesa, Arizona starting in Q3 2009.

(3) Excludes approx. 400 full-time equivalents, who are considered part of corporate overhead with their salaries and benefits included in general and administrative expenses in the Company's condensed consolidated statements of operations. Full-time equivalents included in the above table represent HealthSouth employees who participate in or support the operations of the Company's hospitals.

(4) Employees per occupied bed, or "EPOB," is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company's occupancy percentage.

Payment Sources

	Twelve Months Ended Dec. 31,	
	2009	2008
Medicare	67.9%	67.2%
Medicaid	2.1%	2.2%
Workers' compensation	1.6%	2.1%
Managed care and other discount plans ⁽¹⁾	23.1%	22.4%
Other third-party payors	2.7%	3.5%
Patients	1.2%	1.0%
Other income	1.4%	1.6%
Total	<u>100.0%</u>	<u>100.0%</u>


(1) Managed Medicare revenues represent ~ 8% and 6% of total revenues for 2009 and 2008, respectively, and are included in "Managed care and other discount plans."

Debt Maturities: No Near-Term Financing Needs

(Millions)

As of December 31, 2009

- Term Loan maturities
- 10.75% Fixed
- 8.125% Fixed
- Capital leases and term loan amortization



Interest Rate Swaps: as of December 31, 2009

(Millions)

<u>Floating Rate Debt Balances</u>	<u>Dec. 31, 2009</u>		<u>Floating Interest Rate</u>	
Advances under \$400 million revolving credit facility	\$	-		Libor plus 275
Term Loan facility due 2013		452.0		Libor plus 225
Term Loan facility due 2015		299.3		Libor plus 375 ⁽¹⁾
Total	\$	<u>751.3</u>		

<u>Swap Settlement</u>	<u>Swap Roll Off Dates</u>		
	<u>Dec. 2009</u>	<u>March 2010</u>	<u>March 2011</u>
<u>Does not Qualify for Hedge Accounting</u> ⁽²⁾			
Net notional amount of interest rate swaps ⁽³⁾	\$ 956.0	\$ 884.0	\$ -
Receive 3 month Libor and pay 5.22% fixed			
<u>Does Qualify for Hedge Accounting</u> ⁽⁴⁾			
Notional amount of the interest rate swap			100.0
Receive 3 month Libor and pay 2.6% fixed			
Notional amount of the interest rate swap			100.0
Receive 3 month Libor and pay 2.9% fixed			

(1) In October 2009, the credit agreement was amended. The maturity for \$300 million of the term loan has been extended to 2015. The extended portion of the term loan will bear an interest rate of Libor plus 375.

(2) Cash settlements flow through investing activities.

(3) In June 2009, we entered into a receive-fixed rate swap as a mirror offset to \$100.0 million of the \$1,056 million interest rate swap.

(4) Forward-starting interest rate swaps (designated as cash flow hedges). Cash settlements will flow through operating activities as part of interest expense.

Debt Schedule

(Millions)

	Debt Balances		2009 YTD Debt Reduction
	Dec. 31, 2009	Dec. 31, 2008	
Advances under \$400 million revolving credit facility, March 2012	\$ -	\$ 40.0	\$ (40.0)
Term loan facility - March 2013, 2015	751.3	783.6	(32.3)
Bonds payable:			
Floating Rate Senior Notes due 2014 (6 month Libor plus 600)	-	366.0	(366.0)
10.75% Senior Notes due 2016	494.9	494.3	0.6
8.125% Senior Notes due 2020	285.2	-	285.2
Other bonds payable	1.8	1.8	-
Other notes payable at interest rates	28.0	12.8	15.2
Capital lease obligations	101.3	114.7	(13.4)
Total	<u>\$ 1,662.5</u>	<u>\$ 1,813.2</u>	<u>\$ (150.7)</u> ⁽¹⁾

Debt to EBITDA⁽²⁾

4.3x

5.3x

⁽¹⁾ The Company had \$80.9 million in cash and cash equivalents as of December 31, 2009.

⁽²⁾ Based on four quarter trailing Adjusted Consolidated EBITDA of \$383.0 million and \$341.2 million, respectively. See reconciliation to GAAP on slides 34 through 35.

Non-Operating Cash/Tax Position

Cash Refunds as of Dec. 31, 2009

- Federal tax recoveries virtually complete.
 - Approx. \$43 million received.
- State tax refunds in progress.
 - Approx. \$21 million received.
 - Approx. \$10 million net receivable on the balance sheet.

GAAP Considerations

- HealthSouth's balance sheet currently reflects a valuation allowance for the potential value of NOLs and future deductions. The valuation allowance is approximately \$893 million.
- GAAP tax rate will net to small amount for foreseeable future as there will be a reduction in the valuation allowance when NOLs are utilized.

Future Cash Tax Payments

- Expect to pay about \$5-7 million per year of income tax.
 - State income tax.
 - Alternative Minimum Tax (AMT).
- The Company does not expect to pay significant federal income taxes for the next 10-12 years, due to approximately \$905 million in deferred tax assets as of 12/31/09 outlined in the Form 10-K to be filed with the SEC. The majority of the deferred tax asset is related to net operating losses (NOLs).
 - At this time, we do not believe the use of NOLs will be limited before they expire, however, no assurances can be provided.
- HealthSouth is not currently subject to an annual use limitation (AUL) under the Internal Revenue Code section 382.
- If we experienced a "change of ownership" as defined by the Internal Revenue Code section 382, we would be subject to an AUL, which is equal to the value of the company at the time of the "change of ownership" multiplied by the long-term tax exempt rate.

Outstanding Share Summary

(Millions)

	<u>4th Qtr.</u> <u>2009</u>	<u>4th Qtr.</u> <u>2008</u>	<u>Year-End</u> <u>2009</u>	<u>Year-End</u> ⁽¹⁾ <u>2008</u>
	Weighted Average for the Period			
Basic Shares outstanding ^{(2) (3)}	92.6	87.4	88.8	83.0
Diluted Shares outstanding ^{(2) (3) (4)}	107.8	100.7	103.3	96.4
	End of Period			
			<u>Year-End</u> <u>2009</u>	<u>Year-End</u> ⁽¹⁾ <u>2008</u>
Basic Shares outstanding ^{(2) (3)}			92.6	87.4
Diluted Shares outstanding ^{(2) (3) (4)}			107.8	100.7

Notes:

- (1) Completed an equity offering for 8.8 million shares on June 27, 2008.
- (2) Does not include 2.0 million warrants issued in connection with a January 2004 loan repaid to Credit Suisse First Boston. In connection with this transaction, we issued warrants to the lender to purchase two million shares of our common stock. Each warrant has a term of ten years from the date of issuance and an exercise price of \$32.50 per share. The warrants were not assumed exercised for dilutive shares outstanding because they were antidilutive in the periods presented.
- (3) The agreement to settle our class action securities litigation received final court approval in January 2007. These shares of common stock and warrants were issued on September 30, 2009. The 5.0 million of common shares are now included in the outstanding shares. The warrants at a strike price of \$41.40 were not assumed exercised for the dilutive shares outstanding because they are anti-dilutive in the periods presented.
- (4) The difference between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock.

Three & Twelve Months Reconciliation of Net Income to Adjusted Income from Continuing Operations and Adjusted Consolidated EBITDA ^{(1) (3)}

(In Millions, Except per Share Data)

	Three Months Ended December 31,				Year Ended December 31,			
	2009	Per Share ⁽²⁾	2008	Per Share ⁽²⁾	2009	Per Share ⁽²⁾	2008	Per Share ⁽²⁾
Net income	\$ 46.9	\$ 0.51	\$ 190.2	\$ 2.18	\$ 128.8	\$ 1.45	\$ 281.8	\$ 3.40
Income from discontinued operations, net of tax, attributable to HealthSouth	(12.5)	(0.14)	(9.0)	(0.10)	(1.5)	(0.02)	(16.6)	(0.20)
Net income attributable to noncontrolling interests	(8.3)	(0.09)	(8.3)	(0.09)	(34.0)	(0.38)	(29.4)	(0.35)
Income from continuing operations attributable to HealthSouth	26.1	0.28	172.9	1.98	93.3	1.05	235.8	2.84
Gain on UBS Settlement	-	-	(121.3)	(1.39)	-	-	(121.3)	(1.46)
Government, class action, and related settlements	(4.6)	(0.05)	(39.3)	(0.45)	36.7	0.41	(67.2)	(0.81)
Professional fees – accounting, tax, and legal	3.8	0.04	31.5	0.36	8.8	0.10	44.4	0.53
Loss on interest rate swaps	2.9	0.03	39.6	0.45	19.6	0.22	55.7	0.67
Accelerated depreciation of corporate campus	-	-	-	-	-	-	10.0	0.12
Interest associated with UBS Settlement	-	-	(9.4)	(0.11)	-	-	(9.4)	(0.11)
Adjustment for prior period amounts in tax provision	(4.1)	(0.04)	(49.7)	(0.57)	(8.8)	(0.10)	(75.1)	(0.90)
Adjusted income from continuing operations ^{(1) (3)}	24.1	0.26	24.3	0.28	149.6	1.68	72.9	0.88
Adjustment for dilution ⁽²⁾		(0.04)		(0.04)		(0.23)		(0.12)
Adjusted income from continuing operations per dikuted share ^{(2) (3)}		\$ 0.22		\$ 0.24		\$ 1.45		\$ 0.76
Current period amounts in tax provision	1.7		1.3		5.6		5.0	
Interest expense and amortization of debt discounts and fees, excluding interest associated with UBS Settlement	30.8		37.8		125.8		168.9	
Depreciation and amortization, excluding accelerated depreciation of corporate campus	18.1		17.7		70.9		72.4	
Other adjustments per the Company's credit agreement:	74.7		81.1		351.9		319.2	
Impairment charges, including investments	0.2		1.8		1.4		2.4	
Net noncash loss on disposal of assets	0.5		1.4		3.5		2.0	
Loss on early extinguishment of debt	15.6		0.1		12.5		5.9	
Stock-based compensation expense	3.4		3.2		13.4		11.7	
Other	0.3		(0.1)		0.3		-	
Adjusted Consolidated EBITDA ^{(1) (3) (4)}	\$ 94.7		\$ 87.5		\$ 383.0		\$ 341.2	
Weighted average common shares outstanding:				87.4				
Basic		<u>92.6</u>		<u>100.7</u>		<u>88.8</u>		<u>83.0</u>
Diluted		<u>107.8</u>				<u>103.3</u>		<u>96.4</u>

(1) (2) (3) (4) – Notes on page 35.

Reconciliation Notes

1. Adjusted income from continuing operations and Adjusted Consolidated EBITDA are non-GAAP financial measures. The Company's leverage ratio (Total Consolidated Debt to Adjusted Consolidated EBITDA for the trailing four quarters) is, likewise, a non-GAAP financial measure. Management and some members of the investment community utilize adjusted income from continuing operations as a financial measure and Adjusted Consolidated EBITDA and leverage ratio as liquidity measures on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating these adjusted measures, the reader should be aware that in the future HealthSouth may incur expenses similar to the adjustments set forth above.
2. Per share amounts for each period presented are based on basic weighted average common shares outstanding for all amounts except adjusted income from continuing operations per diluted share, which is based on diluted weighted average shares outstanding. The difference in shares between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock.
3. Adjusted income from continuing operations per diluted share and Adjusted Consolidated EBITDA are two components of our guidance.
4. The Company's Credit Agreement allows certain other items to be added to arrive at Adjusted Consolidated EBITDA, and there may be certain other deductions required.